title: The role of ovarian ablation in the adjuvant therapy of breast cancer.
abstract: Increasing interest has emerged in the role of ovarian function suppression, which has shown equivalence to adjuvant CMF (cyclophosphamide, methotrexate, 5-fluorouracil), whether achieved by surgery or irradiation, in breast cancer patients. Studies have suggested temporary amenorrhea can confer benefit in early breast cancer, giving luteinizing hormone-releasing hormone (LH-RH) agonists an advantage over oophorectomy or radiation. Compared with no therapy, LH-RH agonists reduce risks of recurrence and death among women younger than 50 years of age who have hormone receptor-positive tumors. Trials are assessing the benefits of adding LH-RH agonists to aromatase inhibitors, tamoxifen, or after chemotherapy in women remaining premenopausal, and the necessity for adjuvant chemotherapy with combined ovarian ablation and antiestrogen therapy.
authors: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1-189, Baltimore, MD 21231, USA.
authors: Sing-Huang
authors: SH
authors: Tan
authors: Antonio C
authors: AC
authors: Wolff
mesh_terms: D000568:Amenorrhea / Q000139:chemically induced; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006801:Humans; D010052:Ovariectomy; D010053:Ovary / Q000187:drug effects*; D011878:Radiotherapy; D013629:Tamoxifen / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D007987:Gonadotropin-Releasing Hormone